secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-062918
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Q3 net loss $23.1M; appoints new CEO, restructures to extend cash runway into 2026
--------------------------------------------------------------------------------

- Net loss of $23.1M ($0.32/share) vs $17.8M loss in Q3 2022; revenue of $7.0M from Everest upfront.
- Cash, equivalents, marketable securities $218.2M at Sep 30, down from $276.6M at Dec 31, 2022.
- Co-founder Christopher Kirk appointed CEO Nov 7, replacing John Fowler who remains on board.
- Strategic restructuring pauses drug discovery, extends cash runway into late 2026; focuses on zetomipzomib and KZR-261.
- Collaboration with Everest Medicines for zetomipzomib in Greater China, South Korea, SE Asia; Everest joins PALIZADE trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023062918/0000950170-23-062918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023062918/kzr-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer